{"id":"NCT02889796","sponsor":"Gilead Sciences","briefTitle":"Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","officialTitle":"A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08-30","primaryCompletion":"2018-07-04","completion":"2019-06-20","firstPosted":"2016-09-07","resultsPosted":"2021-01-19","lastUpdate":"2021-06-09"},"enrollment":1759,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Filgotinib","otherNames":["GS-6034"]},{"type":"DRUG","name":"Placebo to match filgotinib","otherNames":[]},{"type":"DRUG","name":"Adalimumab","otherNames":[]},{"type":"DRUG","name":"Placebo to match adalimumab","otherNames":[]},{"type":"DRUG","name":"MTX","otherNames":[]}],"arms":[{"label":"Filgotinib 200 mg","type":"EXPERIMENTAL"},{"label":"Filgotinib 100 mg","type":"EXPERIMENTAL"},{"label":"Adalimumab","type":"ACTIVE_COMPARATOR"},{"label":"Placebo to Filgotinib 200 mg","type":"EXPERIMENTAL"},{"label":"Placebo to Filgotinib 100 mg","type":"EXPERIMENTAL"},{"label":"Placebo Never Received Filgotinib","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Filgotinib 200 mg","deltaMin":76.6,"sd":null},{"arm":"Filgotinib 100 mg","deltaMin":69.8,"sd":null},{"arm":"Adalimumab","deltaMin":70.5,"sd":null},{"arm":"Placebo","deltaMin":49.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"<0.001"},{"comp":"OG001 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":230,"countries":["United States","Argentina","Australia","Belgium","Bulgaria","Canada","Czechia","Germany","Hong Kong","Hungary","India","Ireland","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Poland","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["39592547","39331638","38985247","38057656","37747626","37490202","36327094","36205910","34980223","33504485"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":475},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Alanine aminotransferase increased","Urinary tract infection","Aspartate aminotransferase increased"]}}